Knochensarkome.

Knochensarkome. Z Orthop Unfall. 2018 Feb;156(1):105-124 Authors: Hardes J, Gosheger G, Budny T Abstract Bone sarcomas are extremely rare representing approximately 0.2% among all cancer types. Due to the rarity of these tumors both the patients and the physicians can overlook or misinterpret the first often unspecific symptoms of these tumors (pain, limping and swelling). Therefore, radiographic examination (X-ray and/or MRI) of the involved region in case of inexplicable symptoms is strongly recommended. The most common primary malignant bone tumor entity is osteosarcoma, followed by chondrosarcoma and Ewing sarcoma. Osteosarcomas and Ewing sarcomas occur predominantly in children, adolescents and young adults, while chondrosarcomas primarily affect older patients. Most of the tumors are located in the extremities and the pelvis and in about 90% of cases the surgical treatment can be performed by means of a limb-sparing wide resection. An endoprosthetic or biological reconstruction of the resulting defect, depending on several patient- und tumor-related factors, usually is necessary. Apart from the surgical treatment, patients with osteosarcoma and Ewing sarcoma require a pre- and postoperative chemotherapy, while Ewing sarcoma patients often undergo radiation therapy as well - in some cases as the only local therapy option. Regular follow-up examinations are required after the completion of treatment for the early detection and management of local and/...
Source: Zeitschrift fur Orthopadie und Unfallchirurgie - Category: Orthopaedics Tags: Z Orthop Unfall Source Type: research

Related Links:

Publication date: Available online 21 November 2019Source: Journal of Cancer PolicyAuthor(s): Brandon Maser, Lisa M. Force, Paola Friedrich, Federico Antillon, Ramandeep S. Arora, Cristian A. Herrera, Carlos Rodriguez-Galindo, Rifat Atun, Avram DenburgAbstractTo help understand how health systems and sociopolitical contexts intersect with and impact the performance of childhood cancer care in low- and middle-income countries (LMICs), we have developed a systems-level framework for analyzing the performance of LMIC childhood cancer programs within their health system contexts: The Paediatric Oncology System Integration Tool...
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
Date: Thursday, 12 19, 2019; Speaker: Cristine Delnevo, Ph.D., M.P.H., F.A.A.H.B., Director, Center for Tobacco Studies, Society and Policy Rutgers School of Public Health; Nir Eyal, D.Phil, Director, Center for Population-Level Bioethics (CPLB), Society and Policy Rutgers School of Public Health; https://epi.grants.cancer.gov/events/enrich-forum/
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 12 03, 2019; Speaker: Erikka Loftfield, Ph.D., M.P.H., Research Fellow, Division of Cancer Epidemiology and Genetics (NCI); https://metabolomics-sig.nih.gov/events.html
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Monday, 12 09, 2019; Speaker: Sharon Cantor, Dr., University of Massachusetts Medical School; Building: Building 31; 2A48
Source: NIH Calendar of Events - Category: American Health Source Type: events
CONCLUSION: This mini-review will explain the present research status of Apigenin and will further throw some light on how Apigenin performs its anti-cancerous actions by interfering with the key cell-signaling pathways. PMID: 31746310 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
Nanomedicine, Ahead of Print.
Source: Nanomedicine - Category: Nanotechnology Authors: Source Type: research
CONCLUSIONS: Our observations indicate that treatment of Hep-2 laryngeal cancer cells with ELFEMF for 30 min at 25-50 mT and EP Au-NPs can cause cell damage inducing apoptosis and cell cycle arrest. PMID: 31746453 [PubMed - as supplied by publisher]
Source: Folia Histochemica et Cytobiologica - Category: Cytology Tags: Folia Histochem Cytobiol Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Chemotherapy | Children | Chondrosarcoma | Ewing's Sarcoma | Orthopaedics | Osteosarcoma | Pain | Pain Management | Pathology | Radiation Therapy | Radiography | Radiology | Sarcomas